Table of Contents
Chapter 1: Executive Summary
- Introduction
- Current Status of Pain Therapeutics
- Current Status of Pain Therapeutics
- Pain Therapy Market Dynamics
- Conclusions
Chapter 2: Introduction
- Scope and Nature of the Report
- Format of the Report
Chapter 3: History of Pain Therapeutics
Chapter 4: Current Status of Pain Therapeutics
- The Nature of Pain
- The Neurophysiology of Pain
- Pain Pharmacology Today
- NSAIDs
- Narcotic Analgesics
- Non-Narcotic Analgesics, Including Anti-Migraine Drugs
- Local Anesthetics
- Neuropathic Pain Drugs
- Non-Pharmacological Pain Therapy
- Pain Assessment
- Current Pain Management
- Post-Surgical Pain
- Neuropathic Pain
- Cancer Pain
- HIV/AIDS Pain
- Headache Pain
- Cluster Headaches
- Migraine Headaches
- Tension Headache
- Back Pain
- Arthritis Pain
- Psychogenic Pain
Chapter 5: Current Pain Research and Development
- Basic Research Concepts and Tools
- Pain Research Methodologies
- Animal and Human Models
- In Vitro Methods
- Genomic Methods
- Pain Targets and Compounds
- Ion Channel Targets
- Sodium Channels
- Glutaminergic Channels
- Vanilloid Channels
- Cholinergic Channels
- Other Channels
- GPCR Targets
- Opioid Receptors
- Cannabinoid Receptors
- Other GPCR Receptors
- Development of Medications Addressing Other Mechanisms
- COX-2 Inhibition
- Nitric Oxide Synthase Modulators
- Therapeutic Antibodies and Peptides
- Miscellaneous or Anonymous Mechanisms
- References
Chapter 6: Pain Therapy Market Dynamics
- General Observations
- Strategic Alliances
- Pain Drug R&D Survey
Chapter 7: Company Profiles
- Abbott Laboratories
- Acadia Pharmaceuticals
- Adolor Corporation
- AstraZeneca
- CeNeS Pharmaceuticals plc
- Cognetix, Inc
- Corgentech Inc
- GlaxoSmithKline
- GW Pharmaceuticals
- Johnson & Johnson
- Merck & Co., Inc
- NeurogesX, Inc
- Neuromed Pharmaceuticals Inc
- NeuroTargets Ltd
- Novartis
- PainCeptor Pharma Corp
- Pain Therapeutics, Inc
- Pfizer, Inc
- Pharmos Corporation
- Renovis, Inc
- Rinat Neuroscience Corp
- Synt:em
- Vernalis
- VistaGen Therapeutics, Inc
- Xenome Ltd
- References
Chapter 8: Interviews with Industry Experts
- Franz Hefti, Ph.D., Executive Vice President, Drug Development,
- Rinat Neuroscience
- Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies; Canada
- Research Chair in Genetics of Pain; Dept. of Psychology and Centre for
- Research on Pain; McGill University
- Corey S. Goodman, Ph.D., President, CEO, and Director, Renovis
- Remi Barbier, President, CEO, Chairman, Pain Therapeutics, Inc
- Neil Kurtz, M.D., President and CEO of TorreyPines Therapeutics
Chapter 9: Concluding Comments
| 
View Cart
